Dataset Information

N6-methyladenine-related genes affect biological behavior and the prognosis of glioma.

ABSTRACT:

Background

Although aberrant expression of N6-methyladenine (m⁶ A) methylation-related genes contribute to tumorigenesis in many solid tumors, the prognostic value of the m⁶ A-related genes and their correlation with clinicopathological features in gliomas need advanced study.

Methods

The clinical and sequencing data of 288 patients with glioma were extracted from Chinese Glioma Genome Atlas database. By univariate and multivariable Cox regression analysis, the m⁶ A-related prognostic genes were identified, and their correlation with clinicopathological features was further analysis. A nomogram was constructed by R software and the performance of it was assessed by calibration and time-dependent receiver operating characteristic curve.

Results

Nine m⁶ A-related genes were identified as independent prognostic factors, which were mostly enriched in RNA splicing, regulation of immune response and vesicle-mediated transport. By expression value and regression coefficient of these genes, we constructed risk score of each patient, which was highly associated with clinicopathological features. Kaplan-Meier curve showed that the prognosis of patients with high-risk scores was significantly worse than that with low-risk scores (HR = 4.30, 95% CI = 3.16-5.85, p < 0.0001). A nomogram was constructed based on the nine m⁶ A-related genes signature and clinicopathological features with well-fitted calibration curves (c-index = 0.82), showing high specificity and sensitivity (area under the curve for 1-, 3-, and 5-years survival probability = 0.874, 0.918, and 0.934).

Conclusions

A nine m⁶ A-related genes signature was identified in gliomas. The m⁶ A-related risk score is a novel prognostic factor for patients with glioma, and is associated with clinicopathological features. Moreover, the nomogram based on the nine m⁶ A-related genes signature and clinicopathological features had good efficacy in predicting the survival probability.

SUBMITTER: Qu S

PROVIDER: S-EPMC7826482 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

N6-methyladenine-related genes affect biological behavior and the prognosis of glioma.

Qu Shanqiang S Chen Zhixin Z Liu Bin B Liu Jin J Wang Huafu H

Cancer medicine 20201202 1

<h4>Background</h4>Although aberrant expression of N6-methyladenine (m<sup>6</sup> A) methylation-related genes contribute to tumorigenesis in many solid tumors, the prognostic value of the m<sup>6</sup> A-related genes and their correlation with clinicopathological features in gliomas need advanced study.<h4>Methods</h4>The clinical and sequencing data of 288 patients with glioma were extracted from Chinese Glioma Genome Atlas database. By univariate and multivariable Cox regression analysis, t ...[more]

PMID: 33264518

Similar Datasets

Project description:Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive pulmonary fibrotic disease with unknown etiology and poor outcomes. It severely affects the quality of life. In this study, we comprehensively analyzed the expression of N6-methyladenosine (m6A) RNA methylation regulators using gene expression data from various tissue sources in IPF patients and healthy volunteers. Methods: The gene expression matrix and clinical characteristics of IPF patients were retrieved from the Gene Expression Omnibus database. A random forest model was used to construct diagnosis signature m6A regulators. Regression analysis and correlation analysis were used to identify prognosis m6A regulators. Consensus cluster analysis was used to construct different m6A prognosis risk groups, then functional enrichment, immune infiltration and drug sensitivity analysis were performed. Result: Five candidate m6A genes from lung tissue were used to predict the incidence, and the incidence was validated using datasets from bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells. Subsequently, the BALF dataset containing outcomes data was used for the prognosis analysis of m6A regulators. METTL14, G3BP2, and ZC3H13 were independent protective factors. Using correlation analysis with lung function in the lung tissue-derived dataset, METTL14 was a protective factor in IPF. Based on METTL14 and G3BP2, a consensus cluster analysis was applied to distinguish the prognostic m6A regulation patterns. The low-risk group's prognosis was significantly better than the high-risk group. Biological processes regulated by various risk groups included fibrogenesis and cell adhesion. Analysis of immune cell infiltration showed upregulation of neutrophils in the m6A high-risk group. Subsequently, five m6A high-risk group sensitive drugs and one m6A low-risk group sensitive drug were identified. Discussion: These findings suggest that m6A regulators are involved in the diagnosis and prognosis of IPF, and m6A patterns are a method to identify IPF outcomes.

Project description:BackgroundIn recent years, the prevalence of Alzheimer's disease (AD) has increased, which places a great burden on society and families and creates considerable challenges for medical services. N6-methyladenine (m6A) deoxyribonucleic acid (DNA) adenine methylation is a novel biomarker and is abundant in the brain, but less common in AD. We support to analyze the relationship between DNA m6A and cognition in patients with AD and normal controls (NCs) in China.AimTo analyze the relationship between the novel m6A DNA and cognition in patients with AD and NCs in China.MethodsA total of 179 AD patients (mean age 71.60 ± 9.89 years; males: 91; females: 88) and 147 NCs (mean age 69.59 ± 11.22 years; males: 77; females: 70) who were age- and sex-matched were included in our study. All subjects underwent neuropsychological scale assessment and magnetic resonance imaging examination. Apolipoprotein E (APOE) genotypes were measured through agarose gel electrophoresis. Global m6A levels were evaluated by a MethylFlash m6A DNA Methylation ELISA Kit (colorimetric). Global m6A levels in total DNA from ten AD patients with 18F-AV-45 (florbetapir) positron emission tomography (PET) positivity and ten NCs with PET negativity were analyzed by dot blotting to determine the results.ResultsOur ELISA results showed that the global m6A DNA levels in peripheral blood were different between patients with AD and NCs (P = 0.002; < 0.05). And ten AD patients who were PET positive and ten NCs who were PET negative also showed the same results through dot blotting. There were significant differences between the two groups, which indicated that the leukocyte m6A DNA levels were different (P = 0.005; < 0.05). The m6A level was approximately 8.33% lower in AD patients than in NCs (mean 0.011 ± 0.006 vs 0.012 ± 0.005). A significant correlation was found between the Montreal Cognitive Assessment score and the peripheral blood m6A level in the tested population (r = 0.143, P = 0.01; < 0.05). However, no relationship was found with APOE ε4 (P = 0.633, > 0.05). Further studies should be performed to validate these findings.ConclusionOur results show that reduced global m6A DNA methylation levels are significantly lower in AD patients than in NCs by approximately 8.33% in China.

Dataset Information

N6-methyladenine-related genes affect biological behavior and the prognosis of glioma.

Background

Methods

Results

Conclusions

Publications

N6-methyladenine-related genes affect biological behavior and the prognosis of glioma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets